On the Record · Pfizer
Pfizer layoffs, on the record
Every job cut, severance charge and restructuring Pfizer reported in its annual reports, 2022 to 2025, quoted from the filings.
Job cuts, severance and restructuring
None of Pfizer’s annual reports for 2022 to 2025 describes a layoff, workforce reduction or restructuring.
| Fiscal year ended | Severance costs | Restructuring charges | Restructuring costs incurred |
|---|---|---|---|
| 2016-12-31 | $839 million | $1.05 billion | — |
| 2017-12-31 | −$181 million | $30 million | — |
| 2018-12-31 | $473 million | $796 million | $1.4 billion |
| 2019-12-31 | $108 million | $227 million | $967 million |
| 2020-12-31 | $474 million | $535 million | — |
| 2021-12-31 | $680 million | $741 million | — |
| 2022-12-31 | $776 million | $882 million | — |
| 2023-12-31 | $1.62 billion | $1.97 billion | — |
| 2024-12-31 | $1.15 billion | $1.99 billion | — |
| 2025-12-31 | $684 million | $1.09 billion | — |
Pfizer filed 3 restructuring notices (Form 8-K, Item 2.05) since 2016. This page shows what the company reported to the SEC, not news reports or state layoff notices.
Read from Pfizer’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023, 10-K for 2022) and the financial data it files with the SEC, as of 2026-02-26. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.